Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.

At a dosage of 1.6 g per day, the response was twice as good as placebo, but the difference did not reach statistical significance.

also in 111,027 other papers

r mesalazine compounds involving thou- sands of patients, clear conclusions about the various dosages cannot be made. For sulfasalazine there is a dose-response relation- ship for the treatment of quiescent ulcerative colitis.11 In a recent study the group that received a 3 g dose of Pentasa showed a clear trend towards prolonged remission in the intention to treat analysis, when compared with the 1.5 g group.8 No other data about ulcerative colitis in remission-maintaining studies and dose-response are available.

also in 19,460 other papers